Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GSK Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 May 2017
At a glance
- Drugs GSK 1437173A (Primary)
- Indications Herpes zoster
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Mar 2017 Status changed from not yet recruiting to recruiting.
- 14 Dec 2016 Planned End Date changed from 1 Jul 2018 to 1 Aug 2018.